OBJECTIVES The aim of this study has been determination of the burden of statins in the treatment of acute coronary syndrome (ACS) and angina pectoris (AP). There is a significant number of registered statins (brands and generics) in Belarus (lovastatin, atorvastatin simvastatin and rosuvastatin). Pharmacoeconomic studies of statins are topical because of the competition at the pharmaceutical market to ensure rational use of public and private funds. METHODS Overview of available statins has been conducted. Equivalent effective doses were established on the basis of the published data. "Cost of illness" has been calculated with the help of national clinical guidelines for treatment of ACS and AP. Comparison of the each statin burden by determining the proportion of funds falling at each one in the overall cost of the patient´s care has been made.  RESULTS Cost of statins had no significant value in the overall "cost of illness" for acute coronary pathology (ranged from 0.3% to 1.88%). The cost of statins has a significant impact on the final "cost of illness" in the case of chronic cardiac pathology and ranges from 18.54% to 39.9%. Burden of rosuvastatin (Mertenil) in this analysis seems to be the most stable and predictable because of the changes in a narrow range (23.9% - 26.48% in the first year and 28.48% - 29.49% - the second and subsequent years) vs. atorvastatin (19.35% - 35.7% in the first year and 23.3% - 39.9% in the second and subsequent years) and simvastatin (18.54% - 32.62% in the first year and 22.13% - 35.89% in the second and subsequent years).  CONCLUSIONS Pharmacoeconomic evaluation of statin choosing is important for prolonged use of medicines but not for short-term use in acute coronary syndrome.